Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says

MT Newswires Live06-18

Biogen's (BIIB) decision to advance Diranersen into a phase 3 trial as a treatment for Alzheimer's disease indicates confidence in the drug, Morgan Stanley analysts said in a Thursday note.

The company is scheduled to present data from the phase 2 Diranersen study at the Alzheimer's Association International Conference July 12-15 .

The Morgan Stanley analysts are modeling a Diranersen launch in 2029 and project worldwide sales for the drug at about $3.7 billion by 2035.

Using a 30% probability of success, Morgan Stanley estimates Diranersen sales at $1.3 billion or roughly 10% of the company's total 2035 revenue.

The analysts said that, accounting for Biogen's acquisition of Apellis, they estimate the company's compound annual growth rate from 2026 to 2030 at 1.4%, compared with a decline of 1.2% previously.

Morgan Stanley retained an equal-weight rating on the stock, but increased its price target to $224 from $206.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644085212?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644085212","market":"nz","top_or_hot":-1,"title":"Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Biogen's (BIIB) decision to advance Diranersen into a phase 3 trial as a treatment for Alzheimer's disease indicates confidence in the drug, Morgan Stanley analysts said in a Thursday note.</p><p>The company is scheduled to present data from the phase 2 Diranersen study at the Alzheimer's Association International Conference July 12-15 .</p><p>The Morgan Stanley analysts are modeling a Diranersen launch in 2029 and project worldwide sales for the drug at about $3.7 billion by 2035.</p><p>Using a 30% probability of success, Morgan Stanley estimates Diranersen sales at $1.3 billion or roughly 10% of the company's total 2035 revenue.</p><p>The analysts said that, accounting for Biogen's acquisition of Apellis, they estimate the company's compound annual growth rate from 2026 to 2030 at 1.4%, compared with a decline of 1.2% previously.</p><p>Morgan Stanley retained an equal-weight rating on the stock, but increased its price target to $224 from $206.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-18 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biogen's (BIIB) decision to advance Diranersen into a phase 3 trial as a treatment for Alzheimer's disease indicates confidence in the drug, Morgan Stanley analysts said in a Thursday note.</p><p>The company is scheduled to present data from the phase 2 Diranersen study at the Alzheimer's Association International Conference July 12-15 .</p><p>The Morgan Stanley analysts are modeling a Diranersen launch in 2029 and project worldwide sales for the drug at about $3.7 billion by 2035.</p><p>Using a 30% probability of success, Morgan Stanley estimates Diranersen sales at $1.3 billion or roughly 10% of the company's total 2035 revenue.</p><p>The analysts said that, accounting for Biogen's acquisition of Apellis, they estimate the company's compound annual growth rate from 2026 to 2030 at 1.4%, compared with a decline of 1.2% previously.</p><p>Morgan Stanley retained an equal-weight rating on the stock, but increased its price target to $224 from $206.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644085212","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644085212","pubTimestamp":1781787255,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen's  decision to advance Diranersen into a phase 3 trial as a treatment for Alzheimer's disease indicates confidence in the drug, Morgan Stanley analysts said in a Thursday note.The company is scheduled to present data from the phase 2 Diranersen study at the Alzheimer's Association International Conference July 12-15 .The Morgan Stanley analysts are modeling a Diranersen launch in 2029 and project worldwide sales for the drug at about $3.7 billion by 2035.Using a 30% probability of success, Morgan Stanley estimates Diranersen sales at $1.3 billion or roughly 10% of the company's total 2035 revenue.The analysts said that, accounting for Biogen's acquisition of Apellis, they estimate the company's compound annual growth rate from 2026 to 2030 at 1.4%, compared with a decline of 1.2% previously.Morgan Stanley retained an equal-weight rating on the stock, but increased its price target to $224 from $206.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BIIB":"渤健公司","BK4588":"碎股","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"摩根士丹利表示，百健(Biogen)将Diranersen阿尔茨海默病药物推进到第三阶段显示出信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen's (BIIB) decision to advance Diranersen into a phase 3 trial as a treatment for Alzheimer's disease indicates confidence in the drug, Morgan Stanley analysts said in a Thursday note.The company is scheduled to present data from the phase 2 Diranersen study at the Alzheimer's Association International Conference July 12-15 .The Morgan Stanley analysts are modeling a Diranersen launch in 2029 and project worldwide sales for the drug at about $3.7 billion by 2035.Using a 30% probability of success, Morgan Stanley estimates Diranersen sales at $1.3 billion or roughly 10% of the company's total 2035 revenue.The analysts said that, accounting for Biogen's acquisition of Apellis, they estimate the company's compound annual growth rate from 2026 to 2030 at 1.4%, compared with a decline of 1.2% previously.Morgan Stanley retained an equal-weight rating on the stock, but increased its price target to $224 from $206.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644085212","isCrawlerRequest":true}